Supply Chain Disruptions causes Slow Clean Energy Transition
Revance's Botox Rival Receives USFDA Nod
By Indu Tyagi Ketan , 19 October, 2022
DaxibotulinumtoxinA (Daxxify), Revance's long-awaited Botox rival, has officially received FDA approval, as the company is now gearing up to establish its brand. Daxxify is an intravenous neuromodulator similar to Botox; its novel peptide exchange technology temporarily eases the moderate to severe glabellar (frown) lines.
The trials revealed that a single injection had a significant anti-wrinkle impact on durational effects were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The chief differentiator for Daxxify is its endurance; it can last six months and has even proven effective for up to nine months in some individuals, vis-a-vis Botox injections that last only for three months.
Daxxify was initially scheduled to receive FDA approval in November 2020, but the epidemic slowed inspection. After visiting Revance's production facility, inspectors discovered quality control and record-keeping issues. The FDA then issued Revance a detailed response letter in October of last year. Soon after, the FDA approved the changes in July after Revance resolved all five problems mentioned in the Complete Response Letter.
In a separate report, Goldman Sachs predicted that Revance's Daxxify will cost about 30% more than its competitors, even though pricing has not yet been made public. This cost considers the extended value proposition for both doctors and patients. Revance's stock rose 18% in September post the FDA's approval, which is expected to end Botox's long-standing dominance in the aesthetics industry.
FDA Approves DaxibotulinumtoxinA (Daxxify)
Latest News
Supply Chain Disruptions causes Slow Clean Energy Transition
There is a global race to clean energy sources because of climate change in 2024. However, there is a danger that the impending metal supply crisis will offset this gain. The move to renewable energy technologies greatly depends on critical minerals…
Ag-Tech to Shape India’s Shaking GDP Rates
Indian economy is facing new challenges at the end of the month of 2024. India's gross domestic product (GDP) expanded to 6.7 percent in the second quarter of 2024. From April to June 2024, the Indian market began to shrink continuously. It led to a…
Demand for Oil Slows Down but Not a Crash
Global oil demand reports show unbalanced statistics due to different analyses in two consecutive months of 2024. The International Energy Agency (IEA) states that global oil demand will decline by 2030. The report explains that fossil fuel demand…
China becomes Leading Nation in Manufacturing, Outweighs other Developed Economies
In recent years, China has cemented its reputation as the de facto superpower of the manufacturing sector, eclipsing the likes of the United States of America, Japan, and Germany, which were once considered the leaders in this area. These changes are…
Antiviral Drugs Market against Novel Diseases Surges in 2024
